Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start

Data Mixed In Spinocerebellar Ataxia Study, But Zavegepant PDUFA Date Set

With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.

Exotic rocky road to the crater of the volcano in the famous Caldera of Santorini island — The road to clinical success outside of its CGRP pipeline always has been rocky for Biohaven • Source: Shutterstock

Biohaven Pharmaceutical Holding Company Ltd. said 23 May that troriluzole did not meet the primary endpoint versus placebo in a Phase III clinical trial in spinocerebellar ataxia (SCA) but is holding out hope that the US Food and Drug Administration will endorse a path forward for a subgroup of patients. Still riding high from Pfizer Inc.’s recently announced $11.6bn acquisition of the company’s migraine therapy portfolio, however, Biohaven did not take a big hit from the setback.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

23 Apr 2025

• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Sebela’s Tegoprazan Poised For GERD Market

23 Apr 2025

• By Jessica Merrill

Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).

Pipeline Watch: Eight Approvals And Three Phase III Readouts

23 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

22 Apr 2025

• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

23 Apr 2025

• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.